News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

5 Things Gilead (GILD)'s Q2 Earnings Numbers Didn't Tell You



8/1/2017 6:03:07 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
The numbers didn't lie: Gilead Sciences (NASDAQ:GILD) posted pretty good second-quarter results. While revenue and earnings fell compared to the prior-year period, the big biotech still managed to beat expectations thanks to strong HIV drug sales and a better-than-expected performance from its hepatitis C virus (HCV) franchise. Gilead even upped its full-year 2017 guidance.

Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES